Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885446 | 0.84 | MEN1 (0.47) | ADORA2AALOX5APFEN1MPL | |
| SCHEMBL2390925 | 0.82 | HSD11B1 (0.43) | CTSAALOX5APFEN1HSD11B1MPL | |
| SCHEMBL2387952 | 0.81 | L3MBTL1 (0.42) | CTSAALOX5APFEN1HSD11B1MPL | |
| SCHEMBL1893971 | 0.79 | FEN1 (0.44) | ADORA2AADORA1ALOX5APFEN1HSD11B1 | |
| SCHEMBL1891905 | 0.78 | HSD11B1 (0.50) | CTSAADORA2AADORA1ALOX5APFEN1 | |
| SCHEMBL1891742 | 0.76 | MAP2K4 (0.48) | ADORA2AADORA1ALOX5APFEN1PTGS2 | |
| SCHEMBL1655716 | 0.76 | ADORA2A (0.48) | ADORA2AADORA1ALOX5APFEN1MPL | |
| SCHEMBL2388300 | 0.73 | MEN1 (0.38) | CTSAADORA2AALOX5APFEN1HSD11B1 | |
| SCHEMBL2386528 | 0.73 | L3MBTL1 (0.46) | ADORA2AALOX5APFEN1HSD11B1MPL | |
| SCHEMBL2386650 | 0.73 | MPL (0.41) | CTSAADORA2AADORA1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105543-A1 | NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA3, CHRM3 | CTSA 1864/4885ADORA2A 737/4885ADORA1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.